Edition:
India

Kazia Therapeutics Ltd (KZIA.OQ)

KZIA.OQ on NASDAQ Stock Exchange Capital Market

3.29USD
22 Apr 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.29
Open
$3.55
Day's High
$3.55
Day's Low
$3.29
Volume
340
Avg. Vol
1,264
52-wk High
$5.61
52-wk Low
$2.14

Latest Key Developments (Source: Significant Developments)

Kazia Therapeutics To Sell Remainder Of Holdings In Noxopharm
Tuesday, 19 Mar 2019 

March 19 (Reuters) - Kazia Therapeutics Ltd ::ENTERED INTO AN ARRANGEMENT TO SELL REMAINDER OF ITS HOLDING IN ORDINARY SHARES OF NOXOPHARM LIMITED VIA A SINGLE BLOCK TRADE.TRANSACTION TO YIELD PROCEEDS OF APPROXIMATELY $2.1M.  Full Article

Kazia Therapeutics Announces Uncapped And Not Underwritten Share Purchase Plan At $0.38 Per Share
Tuesday, 23 Oct 2018 

Oct 23 (Reuters) - Kazia Therapeutics Ltd ::ANNOUNCES UNCAPPED AND NOT UNDERWRITTEN SHARE PURCHASE PLAN AT $0.38 PER SHARE.  Full Article

Kazia Therapeutics Enters Clinical Collaboration With Dana-Farber Cancer Institute
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Kazia Therapeutics Ltd ::ENTERS COLLABORATION WITH DANA-FARBER CANCER INSTITUTE TO INVESTIGATE POTENTIAL USE OF NEW DRUG, GDC-0084 IN BREAST CANCER.  Full Article

Kazia Therapeutics Says To Divest A Research Program To Trobio Therapeutics Pty Ltd
Friday, 13 Jul 2018 

July 13 (Reuters) - Kazia Therapeutics Ltd ::TO DIVEST A RESEARCH PROGRAM TO TROBIO THERAPEUTICS PTY LTD .NEGOTIATED DIVESTMENT OF A RESEARCH PROGRAM TO TROBIO THERAPEUTICS PTY LTD, TO TAKE A 12% STAKE IN TROBIO.  Full Article

Kazia Therapeutics And Noxopharm Announce Collaboration
Wednesday, 27 Dec 2017 

Dec 27 (Reuters) - Noxopharm Ltd ::KAZIA THERAPEUTICS AND NOXOPHARM LIMITED ANNOUNCE COLLABORATION TO SUPPORT DEVELOPMENT OF NOXOPHARM LEAD PROGRAM, NOX66..  Full Article

Novogen ‍enters into deal to license & assign preclinical assets
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Novogen Ltd ::‍Entered into agreement to license & assign certain preclinical assets to Heaton-Brown Life Sciences​.‍Under terms of deal, co to receive 10 percent of equity in Heaton-Brown Life Sciences.  Full Article